A phase 1 study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of MEDI9447 alone and in combination with durvalumab (MEDI4736) in patients with advanced solid tumors.

Authors

Johanna C. Bendell

Sarah Cannon Research Institute, Nashville, TN

Johanna C. Bendell , Vijay Reddy , Fatemeh Tavakkoli , Ching Ching Leow , Xia Li , Rakesh Kumar , John H. Strickler

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

A phase 1 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of LB4330, a peptide fused to CLDN18.2 antibody targeting the tumor antigen associated CD8+t CELLS in patients with advanced solid tumors.

First Author: Jiajian Liu

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

A phase 1 study to evaluate the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of the OX40 agonist MEDI0562 in combination with tremelimumab or durvalumab in adult aubjects with advanced solid tumors.

First Author: Brendan D. Curti

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

SELECT-4: Phase I dose escalation trial of selumetinib (AZD6244, ARRY-142886) in combination with durvalumab (MEDI4736) in patients with advanced solid tumors.

First Author: Pasi A. Janne

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

A phase I clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of FN-1501 monotherapy in patients with advanced solid tumors.

First Author: Gary Edward Richardson